TUCSON, Ariz., Dec. 5, 2013 (GLOBE NEWSWIRE) -- Cancer Prevention Pharmaceuticals, Inc., (CPP) announced today the launch of a double-blind, randomized, Phase III trial of the efficacy and safety of CPP-1X/sulindac (eflornithine/sulindac) compared with CPP-1X and sulindac as single agents in 150 patients with Familial Adenomatous Polyposis. Each patient will receive daily treatment for two years to minimize the occurrence and/or recurrence of problematic polyps and tumors associated with this debilitating disease. The trial is being conducted at 8 North American and 4 European clinical trial sites.
Help employers find you! Check out all the jobs and post your resume.
